Ocumension Therapeutics
歐康維視生物

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT
INITIATION OF OT-401 REAL WORLD STUDY IN HAINAN

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the Group has recently initiated the real world study of its core product, OT-401 (YUTIQ) in Boao Super Hospital (博鰲超級醫院) in Hainan province, China, and is recruiting patients simultaneously in various ophthalmic clinical centers across the country. At the same time, a phase III clinical study of OT-401 evaluating the safety and efficacy of fluocinolone vitreous implants in patients with chronic non-infectious uveitis affecting the posterior segment of the eye is also underway in various ophthalmic clinical centers across the country. The real world study data of OT-401 are expected to provide support and supplement to the phase III clinical trial data of OT-401.

The real-world study, a more cost-effective and less time-consuming supplement to the traditional clinical trial, aims to form clinical evidence in relation to the use and potential benefits or risks of medical products by analysing the patient-related data collected in a real-world environment. The initiation of the real world study of OT-401 is expected to accelerate the new drug application registration in China.

OT-401 (YUTIQ), the core product of the Company, is a first-in-class, innovative injectable, sustained-release micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. OT-401 is a sterile non-bioerodible intravitreal implant designed to provide sustained release of a total of 0.18 mg of the active ingredient fluocinolone acetonide, a corticosteroid, at a controlled rate for up to 36 months from a single administration performed in an outpatient visit. To date, YUTIQ is the first and only uveitis treatment designed to deliver fluocinolone for up to 36 months that has been approved by the U.S. Food and Drug Administration.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-401 (YUTIQ) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, November 30, 2020

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.